Page 1

acacia RESEARCH CORPORATION Acacia Research Reports Second Quarter 2021 Financial Results New York , NY , August 16 , 2021 - Acacia Research Corporation ( Nasdaq : ACTG ) today reported results for the three- and six - month periods ended June 30 , 2021 . Clifford Press , Chief Executive Officer , stated , " Our book value continued to grow in the second quarter of 2021 , owing to appreciation in our life science portfolio . Our IP investments over the last year and a half have also begun to deliver growing returns and represent a balanced portfolio across a number of technologies . Acacia remains strategically focused on an opportune part of the capital markets , at the intersection between the private and public market valuations . As a corporate acquirer , we believe that we are an attractive partner to counterparties such as private equity and large enterprises . We have the ability to deploy permanent capital to navigate complex , multi - factor transactions . Our capital base , consisting of cash , public and private investments , and additional available capital pursuant to our partnership with Starboard Value LP , is now $ 770 million and we continue to evaluate and pursue potential acquisitions of operating businesses . " Acacia continued to recognize gains during the second quarter in the value of the life sciences portfolio acquired in June 2020 , driving $ 25.8 million in realized and unrealized gains in the quarter . To date , based on the current value of the portfolio , Acacia has recovered $ 212 million of the purchase price of $ 282 million . As of June 30 , 2021 , Acacia holds the following positions in its life sciences portfolio : Public Company Securities ( at market value at June 30 , 2021 ) Company Arix Bioscience plc Induction Healthcare Group plc Total Public Holdings Company Oxford Nanopore Technologies ¹ Immunocore ² Next three positions : ³ 3 Viamet Pharmaceuticals AMO Pharma NovaBiotics Total Private Holdings Ticker LSE : ARIX AIM : INHC 4844-1113-5478v2 / 101022-0000 Number of Shares 3 Value based on cost . Amounts may not add up due to rounding . 25.8 mm 4.2 mm Ownership Percentage 6 % 4 % Private Company Securities ( at June 30 , 2021 ) 26 % 24 % 4 % Value $ 62.5 mm $ 4.2 mm $ 66.7 mm GAAP Value $ 170.2 mm $ 54.7 mm $ 25.4 mm $ 250.3 mm Change since 3/31 $ ( 5.3 ) mm $ ( 2.0 ) mm ¹ Value of Oxford Nanopore Technologies securities based on the value attributed to these securities in third party transactions . 2 Acacia's class of Immunocore shares do not trade publicly ; value based on equivalent ADS price . $ ( 7.2 ) mm